{
  "docId": "019de070-ff46-75e9-a6a2-27d0e899d3b8",
  "docSlug": "714b2223d61a474cc0c3d011e3fc18ab",
  "documentTitle": "Centessa | IPO Presentation Deck | 33 slides",
  "authorId": "centessa",
  "authorName": "Centessa Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7843866,
  "pageNumber": 17,
  "pageCount": 33,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a three-column layout to summarize the company's core value proposition.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-ff46-75e9-a6a2-27d0e899d3b8/17",
  "deckHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8",
  "deckJsonHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8.json",
  "deckAnchorHref": "/decks/019de070-ff46-75e9-a6a2-27d0e899d3b8#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.92,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "callout",
      "text": "Developing SerpinPC, a Phase 2 stage specific inhibitor of activated protein C (APC) for treatment of hemophilia A & B (HA, HB)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe9e3752-9d8c-47ee-80ef-f899d2be146f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.69,
        "y": 0.45
      },
      "kind": "list",
      "text": "Market opportunity: Estimated global prevalence of HA and HB ~400,000 individuals; ~$11 billion global hemophilia market",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e769073-feaa-44ad-b1cb-a7e92e82d3d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.04,
        "y": 0.45
      },
      "kind": "list",
      "text": "Mission: Develop a monthly subcutaneous therapeutic for hemophilia A & B patients that significantly reduces bleeding rates and avoids excessive blood coagulation via inhibition of activated protein C",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8577b06d-ced0-455f-9f14-933811f12fd1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.32,
        "x": 0.35,
        "y": 0.45
      },
      "kind": "list",
      "text": "De-risking data: Coinheritance of Factor V Leiden mutation (reduced APC) with hemophilia associated with mild bleeding phenotype; Single injection of SerpinPC in 12 subjects with severe hemophilia resulted in marked reduction in all bleeds; Lack of D-dimer elevation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0981efb-ef1a-423c-a51c-c875da3cfec5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.15,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "ApcinteX",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ded110df-0555-4949-8ddd-f38768cda319",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "5872b170-bb8a-4d8f-85ee-e56a6de1a8b0",
      "evidence": "type: executive_summary",
      "confidence": 0.9
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "956f3e8d-4e76-4ca2-96a2-ab5a05a1df75",
      "evidence": "list/bullet: Mission: Develop a monthly subcutaneous therapeutic for hemophilia A & B patients...",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}